Literature DB >> 28941089

Improving outcomes of first-episode psychosis: an overview.

Paolo Fusar-Poli1,2, Patrick D McGorry3, John M Kane4.   

Abstract

Outcomes of psychotic disorders are associated with high personal, familiar, societal and clinical burden. There is thus an urgent clinical and societal need for improving those outcomes. Recent advances in research knowledge have opened new opportunities for ameliorating outcomes of psychosis during its early clinical stages. This paper critically reviews these opportunities, summarizing the state-of-the-art knowledge and focusing on recent discoveries and future avenues for first episode research and clinical interventions. Candidate targets for primary universal prevention of psychosis at the population level are discussed. Potentials offered by primary selective prevention in asymptomatic subgroups (stage 0) are presented. Achievements of primary selected prevention in individuals at clinical high risk for psychosis (stage 1) are summarized, along with challenges and limitations of its implementation in clinical practice. Early intervention and secondary prevention strategies at the time of a first episode of psychosis (stage 2) are critically discussed, with a particular focus on minimizing the duration of untreated psychosis, improving treatment response, increasing patients' satisfaction with treatment, reducing illicit substance abuse and preventing relapses. Early intervention and tertiary prevention strategies at the time of an incomplete recovery (stage 3) are further discussed, in particular with respect to addressing treatment resistance, improving well-being and social skills with reduction of burden on the family, treatment of comorbid substance use, and prevention of multiple relapses and disease progression. In conclusion, to improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is necessary to globally adopt complex models integrating a clinical staging framework and coordinated specialty care programmes that offer pre-emptive interventions to high-risk groups identified across the early stages of the disorder. Only a systematic implementation of these models of care in the national health care systems will render these strategies accessible to the 23 million people worldwide suffering from the most severe psychiatric disorders.
© 2017 World Psychiatric Association.

Entities:  

Keywords:  Psychosis; clinical high risk; clinical staging; first episode psychosis; indicated prevention; outcomes; psychosis risk; schizophrenia; selective prevention; universal prevention

Year:  2017        PMID: 28941089      PMCID: PMC5608829          DOI: 10.1002/wps.20446

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  171 in total

1.  Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more.

Authors:  Patrick McGorry; Mario Alvarez-Jimenez; Eoin Killackey
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

Review 2.  Psychobiologic correlates of treatment response in schizophrenia.

Authors:  J A Lieberman; J M Alvir; A Koreen; S Geisler; M Chakos; B Sheitman; M Woerner
Journal:  Neuropsychopharmacology       Date:  1996-03       Impact factor: 7.853

3.  Recovery, not progressive deterioration, should be the expectation in schizophrenia.

Authors:  Robert B Zipursky; Ofer Agid
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

4.  The Clinical High-Risk State for Psychosis (CHR-P), Version II.

Authors:  Paolo Fusar-Poli
Journal:  Schizophr Bull       Date:  2017-01       Impact factor: 9.306

Review 5.  Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

Authors:  Robin M Murray; Diego Quattrone; Sridhar Natesan; Jim van Os; Merete Nordentoft; Oliver Howes; Marta Di Forti; David Taylor
Journal:  Br J Psychiatry       Date:  2016-11       Impact factor: 9.319

Review 6.  [Advocacy for the establishment of a comprehensive strategy to reduce the "burden" of schizophrenic disorders].

Authors:  D Leguay
Journal:  Encephale       Date:  2016-09-09       Impact factor: 1.291

7.  Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis.

Authors:  Ingrid Melle; Tor K Larsen; Ulrik Haahr; Svein Friis; Jan O Johannesen; Stein Opjordsmoen; Bjørn R Rund; Erik Simonsen; Per Vaglum; Thomas McGlashan
Journal:  Arch Gen Psychiatry       Date:  2008-06

8.  Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort.

Authors:  Stephen F Austin; Ole Mors; Esben Budtz-Jørgensen; Rikke Gry Secher; Carsten R Hjorthøj; Mette Bertelsen; Pia Jeppesen; Lone Petersen; Anne Thorup; Merete Nordentoft
Journal:  Schizophr Res       Date:  2015-08-08       Impact factor: 4.939

Review 9.  Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses.

Authors:  James B Kirkbride; Antonia Errazuriz; Tim J Croudace; Craig Morgan; Daniel Jackson; Jane Boydell; Robin M Murray; Peter B Jones
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

10.  Towards a Standard Psychometric Diagnostic Interview for Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS.

Authors:  P Fusar-Poli; M Cappucciati; G Rutigliano; T Y Lee; Q Beverly; I Bonoldi; J Lelli; S J Kaar; E Gago; M Rocchetti; R Patel; V Bhavsar; S Tognin; S Badger; M Calem; K Lim; J S Kwon; J Perez; P McGuire
Journal:  Psychiatry J       Date:  2016-05-30
View more
  108 in total

1.  Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project.

Authors:  Michele Poletti; Lorenzo Pelizza; Silvia Azzali; Federica Paterlini; Sara Garlassi; Ilaria Scazza; Luigi Rocco Chiri; Eva Gebhardt; Simona Pupo; Raballo Andrea
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-12-01       Impact factor: 4.785

2.  Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis.

Authors:  Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

3.  Psychopathology in 7-year-old children with familial high risk of developing schizophrenia spectrum psychosis or bipolar disorder - The Danish High Risk and Resilience Study - VIA 7, a population-based cohort study.

Authors:  Ditte Ellersgaard; Kerstin Jessica Plessen; Jens Richardt Jepsen; Katrine Soeborg Spang; Nicoline Hemager; Birgitte Klee Burton; Camilla Jerlang Christiani; Maja Gregersen; Anne Søndergaard; Md Jamal Uddin; Gry Poulsen; Aja Greve; Ditte Gantriis; Ole Mors; Merete Nordentoft; Anne Amalie Elgaard Thorup
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  The Centroid Cannot Hold: Comparing Sequential and Global Estimates of Coherence as Indicators of Formal Thought Disorder.

Authors:  Weizhe Xu; Jake Portanova; Ayesha Chander; Dror Ben-Zeev; Trevor Cohen
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

5.  Current goals of neuroimaging for mental disorders: a report by the WPA Section on Neuroimaging in Psychiatry.

Authors:  Giulia Maria Giordano; Stefan Borgwardt
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

6.  Progress in Schizophrenia Research and Treatment.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

7.  Enhancing the Engagement of Immigrant and Ethnocultural Minority Clients in Canadian Early Intervention Services for Psychosis.

Authors:  Anika Maraj; Srividya N Iyer; Jai L Shah
Journal:  Can J Psychiatry       Date:  2018-08-01       Impact factor: 4.356

8.  Validation of the Prodromal Questionnaire-Brief in a representative sample of adolescents: Internal structure, norms, reliability, and links with psychopathology.

Authors:  Eduardo Fonseca-Pedrero; Felix Inchausti; Alicia Pérez-Albéniz; Javier Ortuño-Sierra
Journal:  Int J Methods Psychiatr Res       Date:  2018-09-10       Impact factor: 4.035

9.  "Throwing out the baby with the bathwater"? Conceptual and methodological limitations of the HiTOP approach.

Authors:  Hans-Ulrich Wittchen; Katja Beesdo-Baum
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

10.  Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use.

Authors:  Daniel Guinart; Estefanía Moreno; Liliana Galindo; Aida Cuenca-Royo; Marta Barrera-Conde; Ezequiel J Pérez; Cristina Fernández-Avilés; Christoph U Correll; Enric I Canela; Vicent Casadó; Arnau Cordomi; Leonardo Pardo; Rafael de la Torre; Víctor Pérez; Patricia Robledo
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.